Venturi Wealth Management LLC Has $324,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Venturi Wealth Management LLC boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 60.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,625 shares of the medical equipment provider’s stock after acquiring an additional 1,359 shares during the period. Venturi Wealth Management LLC’s holdings in Lantheus were worth $324,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC boosted its position in shares of Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Moloney Securities Asset Management LLC bought a new position in Lantheus during the third quarter worth about $1,066,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Lantheus during the 3rd quarter worth about $25,955,000. Van ECK Associates Corp increased its stake in shares of Lantheus by 58.6% in the 3rd quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after acquiring an additional 21,604 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Lantheus by 47.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after acquiring an additional 3,772 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of analyst reports. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities restated a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. Finally, Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Down 0.6 %

Shares of LNTH stock opened at $80.88 on Friday. The company has a market capitalization of $5.62 billion, a price-to-earnings ratio of 13.46 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $56.06 and a 12-month high of $126.89. The firm has a fifty day moving average of $90.60 and a 200-day moving average of $97.20.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.